#1 Clinical Trials Search in Europe

Human Papillomavirus Type 58 L1 Protein

This article summarizes several clinical trials investigating the use of Human Papillomavirus Type 58 L1 Protein as part of a 9-valent HPV vaccine (9vHPV). These studies aim to evaluate the vaccine’s efficacy, safety, and immunogenicity in various populations and medical conditions. The trials explore different dosing regimens, timing of vaccination, and potential therapeutic applications beyond standard preventive use.

Table of Contents

What is Human Papillomavirus Type 58 L1 Protein?

Human Papillomavirus Type 58 L1 Protein is one of the components in the 9-valent HPV vaccine, also known as Gardasil 9. This protein is a part of the outer shell (capsid) of the Human Papillomavirus Type 58. In the vaccine, it’s present in the form of virus-like particles (VLPs), which mimic the structure of the real virus but don’t contain any genetic material that could cause an infection.[1]

Vaccine Composition and How It Works

The 9-valent HPV vaccine contains L1 proteins from nine different HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. These proteins are produced using recombinant DNA technology in yeast cells (specifically, Saccharomyces cerevisiae). The vaccine works by stimulating the immune system to produce antibodies against these HPV types, providing protection against future infections.[1]

Diseases Prevented by the Vaccine

The 9-valent HPV vaccine, including the Type 58 L1 protein, helps prevent several HPV-related diseases:

  • Cervical, vaginal, vulvar, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
  • Genital warts caused by HPV types 6 and 11
  • Precancerous lesions caused by these HPV types

By including protection against HPV type 58, the vaccine offers broader coverage against potential cancer-causing HPV strains.[2]

Who Should Get Vaccinated?

The HPV vaccine is recommended for:

  • Girls and boys aged 9-14 years (primary target group for vaccination programs)
  • Women up to 26 years old who haven’t been previously vaccinated
  • Men up to 26 years old (in some countries)

Some ongoing studies are also evaluating the vaccine’s effectiveness in older age groups and specific populations, such as immunocompromised individuals.[3]

Dosing Schedule

The typical dosing schedule for the 9-valent HPV vaccine is:

  • For individuals 9-14 years old: 2 doses, with the second dose given 6-12 months after the first
  • For individuals 15 years and older: 3 doses, with the second dose given 2 months after the first, and the third dose given 6 months after the first

Some studies are exploring extended dosing intervals to potentially improve vaccine effectiveness.[1]

Effectiveness of the Vaccine

Clinical trials have shown that the 9-valent HPV vaccine, including protection against Type 58, is highly effective in preventing HPV infections and related diseases. The vaccine has demonstrated the ability to induce a strong immune response, with high levels of antibodies against the included HPV types, including Type 58.[2]

Safety and Side Effects

The 9-valent HPV vaccine has been extensively tested and is considered safe. Common side effects may include:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness

Serious side effects are rare. As with any vaccine, severe allergic reactions are possible but extremely uncommon.[4]

Ongoing Research

Several clinical trials are currently underway to further evaluate the 9-valent HPV vaccine, including its effectiveness in various populations:

  • Studies on extended dosing intervals to potentially improve vaccine effectiveness[1]
  • Research on the vaccine’s efficacy in immunocompromised children and adolescents[3]
  • Evaluation of the vaccine’s effectiveness in preventing oral HPV infections in adult males[5]
  • Studies on the vaccine’s potential in treating difficult-to-treat palmar or plantar warts[6]

These ongoing studies aim to expand our understanding of the vaccine’s benefits and potentially broaden its applications in preventing HPV-related diseases.

Trial Aspect Details
Study Populations Children and adolescents (9-14 years), young adults (16-26 years), adult males (20-45 years), immunocompromised patients, women with vHSIL, individuals with difficult-to-treat warts
Main Objectives Evaluate safety, immunogenicity, and efficacy of 9vHPV vaccine in various populations and conditions
Dosing Regimens 2-dose and 3-dose schedules, with varying intervals between doses (e.g., 6-60 months for 2-dose, standard 0, 2, 6 months for 3-dose)
Key Outcomes Antibody responses, seroconversion rates, HPV infection prevention, safety profile, quality of life improvements
Special Populations Immunocompromised patients (HIV-infected, transplant recipients, post-chemotherapy), women with vHSIL, individuals with treatment-resistant warts
Novel Applications Therapeutic use in vHSIL, treatment of difficult-to-treat warts, post-treatment vaccination for high-grade cervical lesions

FAQ

  • What is the 9-valent HPV vaccine? The 9-valent HPV vaccine (9vHPV) is a vaccine that protects against nine types of human papillomavirus, including types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is designed to prevent HPV-related diseases such as cervical, vulvar, vaginal, and anal cancers, as well as genital warts.
  • Who are the target populations for these clinical trials? The clinical trials target various populations, including children and adolescents aged 9-14, young adults aged 16-26, adult males aged 20-45, immunocompromised patients, women with vulvar high-grade squamous intraepithelial lesions (vHSIL), and individuals with difficult-to-treat palmar or plantar warts.
  • What are the main objectives of these clinical trials? The main objectives of these trials include evaluating the safety and immunogenicity of different dosing regimens, assessing the vaccine's efficacy in preventing HPV-related infections and diseases, studying its potential therapeutic effects in certain conditions, and investigating its use in specific populations such as immunocompromised patients.
  • How is the vaccine administered in these trials? The vaccine is typically administered as an intramuscular injection. The dosing schedules vary between trials, with some studies comparing 2-dose regimens to 3-dose regimens, while others focus on the standard 3-dose schedule given over 6 months.
  • What are some of the key outcomes being measured in these trials? Key outcomes being measured include antibody responses to HPV types, seroconversion rates, incidence of HPV-related infections and diseases, safety and tolerability of the vaccine, quality of life improvements, and in some cases, clearance of existing HPV infections or related conditions.

Ongoing Clinical Trials on Human Papillomavirus Type 58 L1 Protein

  • Study on HPV Vaccine Timing for Patients After Stem Cell Transplantation Using Gardasil 9

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various types of cancer and genital warts. There are many different types of HPV, some of which are targeted by vaccines.
  • 9vHPV vaccine: A vaccine that protects against nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58), offering broader protection than earlier HPV vaccines.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response.
  • Geometric Mean Titer (GMT): A way of measuring the average concentration of antibodies in a group of subjects, often used to assess vaccine responses.
  • Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL): A precancerous condition of the vulva that may be caused by persistent HPV infection.
  • Allogeneic stem cell transplantation: A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor.
  • Competitive Luminex Immunoassay (cLIA): A laboratory technique used to measure antibodies against specific HPV types in blood samples.
  • Persistent infection: An infection that continues over time, often used in the context of HPV infections that do not clear naturally.
  • Recombinant vaccine: A vaccine produced through genetic engineering techniques, often used to create virus-like particles that mimic the structure of viruses.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  3. http://clinicaltrials.eu/trial-id/2022-502912-35-00
  4. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  5. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-for-women-with-vulvar-hsil-evaluating-the-effectiveness-of-nonavalent-hpv-vaccine-in-preventing-recurrence-of-vulvar-high-grade-lesions/
  6. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/